2014
DOI: 10.1007/s11060-014-1427-0
|View full text |Cite
|
Sign up to set email alerts
|

Reproductive factors and risk of primary brain tumors in women

Abstract: Gender-specific incidence patterns and the presence of hormonal receptors on tumor cells suggest that sex hormones may play a role in the pathogenesis of primary brain tumors. However, epidemiological studies on the relation of hormonal risk factors to the risk of brain tumors have been inconsistent. We examined the role of reproductive factors in the onset of glioma and meningioma among women enrolled in a case-control study conducted in the Southeastern US that included 507 glioma cases, 247 meningioma cases… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
40
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 49 publications
(42 citation statements)
references
References 59 publications
2
40
0
Order By: Relevance
“…In a case–control study in the USA with 619 women with glioma and 650 controls, self-reported use of hormone replacement therapy (HRT) was associated with an OR of 0.56 (95% CI, 0.37–0.84; Felini et al , 2009). This result is in line with those of a number of other case–control studies of self-reported use of oral contraceptives or HRT, reported separately (Huang et al , 2004; Hatch et al , 2005; Wigertz et al , 2006; Anic et al , 2014), which did not, however, reach statistical significance. In two case–control studies nested in population-based registries, with data on prescriptions collected prospectively and independently of the study hypothesis, use of HRT did not decrease the risk for glioma, based on 689 cases (OR, 1.14; 95% CI, 0.93–1.40) and 658 cases (OR, 0.9; 95% CI, 0.8–1.1; Benson et al , 2015 and Andersen et al , 2013).…”
Section: Exogenous Hormones: Self-reported Use Versus Prescription Datasupporting
confidence: 90%
See 1 more Smart Citation
“…In a case–control study in the USA with 619 women with glioma and 650 controls, self-reported use of hormone replacement therapy (HRT) was associated with an OR of 0.56 (95% CI, 0.37–0.84; Felini et al , 2009). This result is in line with those of a number of other case–control studies of self-reported use of oral contraceptives or HRT, reported separately (Huang et al , 2004; Hatch et al , 2005; Wigertz et al , 2006; Anic et al , 2014), which did not, however, reach statistical significance. In two case–control studies nested in population-based registries, with data on prescriptions collected prospectively and independently of the study hypothesis, use of HRT did not decrease the risk for glioma, based on 689 cases (OR, 1.14; 95% CI, 0.93–1.40) and 658 cases (OR, 0.9; 95% CI, 0.8–1.1; Benson et al , 2015 and Andersen et al , 2013).…”
Section: Exogenous Hormones: Self-reported Use Versus Prescription Datasupporting
confidence: 90%
“…We selected 30 case–control studies and six cohort studies on the association between glioma and medical radiation (Preston-Martin et al , 1989; Neuberger et al , 1991; Schlehofer et al , 1992; Ryan et al , 1992; Zampieri et al , 1994; Ruder et al , 2006; Blettner et al , 2007; Davis et al , 2011), exogenous hormone use (Huang et al , 2004; Hatch et al , 2005; Wigertz et al , 2006; Silvera et al , 2006; Benson et al , 2008, 2015; Felini et al , 2009; Michaud et al , 2010; Kabat et al , 2011; Andersen et al , 2013; Anic et al , 2014; 2015) or allergic diseases (Cicuttini et al , 1997; Schlehofer et al , 1999, 2011; Wiemels et al , 2002, 2004, 2009; Brenner et al , 2002; Schwartzbaum et al , 2003; Schoemaker et al , 2006; Wigertz et al , 2007; Scheurer et al , 2008; Berg-Beckhoff et al , 2009; Il'yasova et al , 2009; 2009; McCarthy et al , 2011; Calboli et al , 2011; Turner et al , 2013; Cahoon et al , 2014). Table 1 lists the key characteristics of the selected studies.…”
mentioning
confidence: 99%
“…The age group analysis showed that the HR of brain tumor in patients aged 50–64 years was significantly higher in the PD group than in the non‐PD group (2.77, 95% CI = 1.07–7.14) but was less obvious in the patients aged ≥65 years (1.92, 95% CI = 0.98–3.79). In the general population, the incidences of certain benign brain tumors (i.e., meningioma) increase with age , which may have caused less of a difference in the occurrence of brain tumors between the older patients of the non‐PD and PD groups.…”
Section: Discussionmentioning
confidence: 99%
“…The lower incidence of CNS tumors in the female population has been related to factors like the protective role of the female hormones and genetic differences between males and females (Gabriella et al, 2014). Also in the recent published research article the researchers found that retinoblastoma protein (Rb), a protein known to reduce cancer risk, is significantly less active in male brain cells than in female brain cells, so males greatly susceptible to brain tumors (Sun et al, 2014).…”
Section: Discussionmentioning
confidence: 99%